Phase III trial programme, ADJUNCT, investigating liraglutide for the treatment of type 1 diabetes mellitus
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2013
At a glance
- Drugs Liraglutide (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms ADJUNCT
- Sponsors Novo Nordisk
- 07 Feb 2013 Planned number of patients changed to 2000.
- 07 Feb 2013 New trial record
- 04 Feb 2013 This programme is being conducted with the intention of further expanding the Victoza label, according to a Novo Nordisk media release.